Afraxis Inc., of San Diego, named Carmine Stengone president and CEO, and Christopher Rex chief scientific officer...Cleveland BioLabs Inc., of Buffalo, N.Y., added Julia Brown and Anthony Principi to its board, and appointed David Hohn board chairman

Aeterna Zentaris Inc., of Quebec City, appointed David A. Dodd president and CEO...Astellas Pharma Inc., of Tokyo, named Songlin Xue head of global pharmacovigilance, and he will be based in the Northbrook, Ill., office...Zosano Pharma Inc., of Fremont, Calif., named Chris Krueger chief business officer and added Kleanthis G. Xanthopoulos to its board

Bristol-Myers Squibb Co., of New York, named Francis Cuss executive vice president and chief scientific officer, effective July 1...EntreMed Inc., of Rockville, Md., appointed Ken K. Ren CEO, and added James Huang and Y. Alexander Wu to its board

F2G Ltd., of Manchester, UK, appointed Ian Nicholson CEO and board member...NeuroVive Pharmaceutical AB, of Lund, Sweden, elected Anna Malm Bernsten and Boel Flodgren to its board...Vermillion Inc., of Austin, Texas, appointed Thomas McLain president and CEO

Champions Oncology Inc., of Hackensack, N.J., added Dan Mendelson and Arthur G...Cytori Therapeutics Inc., of San Diego, named Steven Kesten executive vice president and chief medical officer...OncoSec Medical Inc., of San Diego, appointed Sanjiv S. Agarwala, Axel Hauschild, Kim A. Margolin and Vernon K. Sondak to its new melanoma advisory board (MAB) and named Adil I. Daud chairman of the MAB

Anergis, of Eplinges, Switzerland, named Gilles Della Corte director of clinical development and Eva Castagnetti director of product development...Curis Inc., of Lexington, Mass., appointed Ali Fattaey president and chief operating officer...Mylan Inc., of Pittsburgh, added Melina Higgins and Rajiv Malik to its board

Protea Biosciences Inc., of Morgantown, W. Va., added Thijs Spoor and Josiah T. Austin to its board...Regulus Therapeutics Inc., of La Jolla, Calif., added Mark G. Foletta to its board and audit committee...Soligenix Inc., of Princeton, N.J., appointed Stephen T. Sonis, Dorothy Keefe and Mark Schubert to its newly created medical advisory board, which will deal with SGX942, its treatment for oral mucositis

Probiodrug AG, of Halle, Germany, appointed Ronald Black chief medical officer and Inge Lues chief development officer...Rexahn Pharmaceuticals Inc., of Rockville, Md., named Peter D. Suzdak CEO and Chang AHN chief scientist...Spectrum Pharmaceuticals Inc., of Henderson, Nev., named Joseph Turgeon senior vice president and chief commercial officer

Ambrx Inc., of San Diego, named Lawson Macartney president and CEO...Esperion Therapeutics Inc., of Plymouth, Mich., named Tim Mayleben president and CEO and Roger Newton executive chairman and chief scientific officer...plc, of Dublin, Ireland, added Richard T. Colllier and Shane Cooke to its board

CytRx Corp., of Los Angeles, named Daniel Levitt executive vice president, and he continues as chief medical officer...OvaScience Inc., of Cambridge, Mass., named Alison Lawton chief operating officer and Christopher Beck chief commercial officer...Relypsa Inc., of Redwood City, Calif., added Paul J. Hastings and David W.J. McGirr to its board

CytoDyn Inc., of Portland, Ore., named Michael D. Mulholland chief financial officer, treasurer and corporate secretary, and added Michael Nobel and Allan Green to its board...GeNO LLC, of Waltham, Mass., named Kurt Dasse president and Barry Gellman senior vice president, engineering...IntelliCell BioSciences Inc., of New York, appointed Harry Fisch director of urology and added him to its scientific advisory board

Five Prime Therapeutics Inc., of South San Francisco, appointed Julie Hambleton senior vice president and chief medical officer...ImmunoCellular Therapeutics Ltd., of Los Angeles, named Andrew Gengos president and CEO...Pluristem Therapeutics Inc., of Haifa, Israel, appointed Fred Appelbaum, Richard Champlin, Edwin M. Horwitz, Hillard M. Lazarus, Reuven Or and Jacob M. Rowe to its hematology clinical advisory board

Summit plc, of Oxford, UK, added Jim Mellon and Frank Armstrong to its board...and Justin Smith senior vice president, general manager, U.S. Rx dermatology...Verastem Inc., of Cambridge, Mass., added Alison Lawton and Michael Kauffman to its board

Alimera Sciences Inc., of Atlanta, appointed Philip Ashman senior vice president and European managing director and named Eric Teo vice president and European medical director...Anne-Marie Swift will serve as vice president and European marketing director...Ohr Pharmaceuticals Inc., of New York, added Jeffrey S. Heier and Daniel Roth to its scientific advisory board

Blueprint Medicines, of Cambridge, Mass., appointed Chris Varma president and CEO, and named Daniel S. Lynch executive chairman of its board...HemoShear LLC, of Charlottesville, Va., added Mehmood Khan and Frederick W.K. Brown to its board

Fedora Pharmaceuticals Inc., of Edmonton, Alberta, appointed Ronald W. Odynski and Leonard E. Post to its newly created board, and named Christopher Micetich board chairman...Pharmanest AB, of Stockholm, Sweden, added Per Lango and Gunilla Ekstrom to its board, and named Alan Raffensperger board chairman

Cerecor Inc., of Baltimore, appointed James Vornov senior vice president, clinical development and regulatory affairs, and John Kaiser vice president of commercialization and business development...Fate Therapeutics Inc., of San Diego, appointed Christian Weyer president and CEO

DCPrime BV, of Amsterdam, the Netherlands, named Marcel Zwaal CEO and Anthony Hall chief medical officer...Theratechnologies Inc., of Montreal, appointed Luc Tanguay interim president and CEO...Zyngenia Inc., of Gaithersburg, Md., added Christian Itin and Jason Rhodes to its board

Althea Technologies Inc., of San Diego, named Rick Hancock president and CEO, Chris Duffy senior vice president of operations and E.J. Brandreth senior vice president of quality and regulatory...SpringLeaf Therapeutics Inc., of Boston, appointed Pieter Muntendam president and CEO